Company profile
Pharvaris N.V.
NASDAQ:PHVSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Deucrictibant | phase3 | — | 6 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04618211 | phase2 | completed | 2021-02-03 | 2022-09-23 | Pharvaris Netherlands B.V. | Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema |
| NCT05047185 | phase2 | terminated | 2022-04-19 | 2025-06-30 | Pharvaris Netherlands B.V. | Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II |
| NCT05396105 | phase2_3 | enrolling_by_invitation | 2022-12-28 | 2027-06-01 | Pharvaris Netherlands B.V. | Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema |
| NCT06679881 | phase3 | recruiting | 2025-02-01 | 2028-12-01 | Pharvaris Netherlands B.V. | Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE |
| NCT06669754 | phase3 | active_not_recruiting | 2024-12-01 | 2026-08-01 | Pharvaris Netherlands B.V. | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE |
FDA applications (0)
No records yet.